Roots Analysis has announced the addition of “Biologics Fill Finish Services Market (3rd Edition), 2022-2035” report to its list of offerings.
Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill / finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities.
Key Market Insights
More than 175 service providers claim to offer services for biologic fill / finish operations
The biologics fill / finish market is highly fragmented, featuring a mix of small, mid-sized, and large players. It is worth noting that this market is currently dominated by mid-sized companies (having 51-500 employees), which represent more than 40% of the industry stakeholders, worldwide.
Several partnerships have been established in the biologics fill / finish services domain, since 2013
Nearly 40% of the deals were inked in 2020. Majority of the instances captured in the report were service agreements (60%). In addition, more than 50 deals have been inked by players to offer biologics fill / finish services for vaccines.
Over 170 expansions have been reported in biologics fill / finish services domain, since 2013
More than 50% of the total expansions were focused on enhancing the dedicated capacities, thereby enabling the industry stakeholders to accommodate their growing business and address the surge in the demand for fill / finish services. Further, more than 45% of the expansions involved the establishment of new plant / facilities or adding area to the existing facilities, across different geographical locations.
The currently available biologics fill / finish capacity is estimated to be over 185 Kiloliters
Around 90% of the installed fill / finish capacity belongs to the companies with commercial scale production capabilities. In fact, close to 85% of the available capacity belongs to the large companies (having more than 500 employees).
The demand for biologics fill / finish services is expected to grow at an annualized rate of 14%
Currently, more than 60% of the overall demand for biologics fill/ finish services is generated from filling of vials. Moreover, close to 40% of the demand is likely to be generated in the Europe region.
Europe and Asia-Pacific are expected to capture more than 70% of the market share by 2035
In terms of type of biologics, antibodies and vaccines are expected to occupy a larger share (~70%) of the total biologics fill / finish services market in 2035. Further, over 25% of the biologics fill / finish services market share for therapeutic areas is captured by oncological disorders.
To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/256/request-sample.html
Key Questions Answered
- What is fill / finish?
- Who are the key players offering biologics fill / finish services?
- Where are biologics fill / finish facilities located?
- What is the market share of ampoules, cartridges, vials, and syringes in fill / finish?
- What types of expansion initiatives are being undertaken by players in this domain?
- What is the current demand for biologics fill / finish services?
- What is the current and future market size for biologics fill / finish services?
The financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:
- Type of Packaging Container
- Type of Biologic
- Cell Therapies
- Gene Therapies
- Proteins / Peptides
- Therapeutic Area
- Oncological Disorders
- Autoimmune Disorders
- Infectious Diseases
- Cardiovascular Disorders
- Other Disorders
- Scale of Operation
- Preclinical / Clinical
- Company Size
- Key Geographical Regions
- North America
- Middle East and North Africa
- Latin America
The report features inputs from eminent industry stakeholders, according to whom, a significant increase in the demand for cell and gene therapies is driving the growth of the biologics fill / finish market. The report includes detailed transcripts of discussions held with the following experts:
- Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
- Matt Delaney (Vice President Business Development Marketing, Cytovance Biologics)
- Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
- Ales Sima (Business Development Manager, Oncomed Manufacturing)
- Amit Chandra (Technology Watch Manager, Yposkesi)
- Jos Vergeest (International Business Developer, HALIX)
The research also includes detailed profiles of key players (listed below) engaged in offering biologics fill / finish services; each profile features a brief overview of the company, its financial information (if available), details on biologics fill / finish services, location of facilities recent developments and an informed future outlook.
- AbbVie Contract Manufacturing
- Boehringer Ingelheim BioXcellence
- Catalent Biologics
- Charles River Laboratories
- Fresenius Kabi
- Glaxo SmithKline
- Hetero Drugs
- Intas Pharmaceuticals
- Pierre Fabre
- Samsun Biologics
- Takara Bio
- Wacker Biotech
- WuXi AppTec
- WuXi Biologics
For additional details, please visit
You may also be interested in the following titles:
- Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
- AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
+1 (415) 800 3415